Atlas Trials

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Clinical trial NCT03219775 · UNKNOWN

Trial details

NCT number
NCT03219775
Sponsor
AIO-Studien-gGmbH
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Transitional Cell CarcinomaAdvanced CancerMetastatic Cancer
Start date
2017-07-06
Primary completion
2021-09-16
Enrollment
169

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.